A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:5/3/2014
Start Date:May 2011
Contact:Brenda Souza
Phone:(609) 512-4129

Use our guide to learn which trials are right for you!

An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

The primary objective of this study is to evaluate the safety and tolerability of ONO-7746
across multiple doses in patients with solid tumors and chemotherapy induced
thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive
chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The
secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the
pharmacodynamic effect of ONO-7746 on CIT.


Inclusion Criteria:

- Signed written informed consent

- Age ≥ 18 years

- Patients with confirmed solid tumor and scheduled to receive at least two cycles of
myelosuppressive chemotherapy on Day 1 every 21 days at the same dosage and schedule
in the study.

- Experienced thrombocytopenia as evidenced by a platelet count < 100 Gi/L in the
preceding cycle immediately before study enrollment.

- ECOG performance status ≤ 2

- For females, surgically sterilized, postmenopausal or agree to use an acceptable form
of birth control

- Patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib,
trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by
the investigator and after consultation and approval from the Sponsor

- PT/INR and aPTT are within 80% to 120% of the normal range

Exclusion Criteria:

- Experienced thrombocytopenia as evidenced by a platelet count < 25 Gi/L at any time
in the preceding cycle immediately before enrollment into the study

- History or presence of clinically significant disease

- Received any TRAs, or rHuIL-11 within the last 4 weeks prior to screening

- Had received a bone marrow or peripheral blood stem cell infusion (within 1 year of
screening).

- Pregnant, wanting to become pregnant or lactating
We found this trial at
3
sites
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Augusta, Georgia 30901
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Fort Collins, Colorado 80528
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials